Arcutis Biotherapeutics, Inc. announced the launch of an educational campaign designed to elevate understanding, connection, and encouragement for those living with seborrheic dermatitis, or Seb Derm for short
New results show Lival/Livazo (pitavastatin)from Kyowa Hakko Kirin is as effective as other commonly used statins at lowering low density...
To evaluate the effect of erenumab compared to placebo on the change from baseline in monthly migraine days, in adults with episodic migraine.
Arcutis Biotherapeutics, Inc. announced that the Journal of American Academy of Dermatology (JAAD) published positive results from the pivotal Phase III STRATUM trial evaluating Zoryve (roflumilast) foam, 0.3% as a once-daily steroid-free treatment for seborrheic dermatitis.
Novel imaging agents derived from inhibitors of the enzyme cyclooxygenase-2 (COX-2), could make it possible to "see" inflammation due to...
Varicella-zoster virus causes both varicella (chickenpox) and herpes zoster (shingles). Although varicella incidence has dramatically declined since introduction of the live-attenuated varicella vaccine, vaccination rates are suboptimal, and outbreaks still occur.
Background: While many studies have previously focused on fingolimod's effect on immune cells, the effect it has on circulating and local central nervous system platelets (Plts) has not yet been investigated.
Arcutis Biotherapeutics, Inc. announced a new subgroup analysis highlighting that adults and adolescents with seborrheic dermatitis who are contraindicated, intolerant, or unresponsive to topical steroids were 3.5 times more likely to achieve IGA Success with Zoryve(roflumilast) topical foam, 0.3%, compared to vehicle (78.8% Zoryve foam; 48.3% vehicle; p<0.001)
For cuts, grazes, insect bites, minor wounds, spots, minor burns and scalds.